The Chennai-based Quest Life Sciences, one of the fast growing clinical research organisations (CROs) in India, has acquired Fortis Clinical Research Ltd (FCRL), a division of Fortis Hospitals Group - promoted by Malvinder Singh and Shivinder Singh.  FCRL has been an established BA/BE centre in Faridabad.

FCRL has accreditations from US FDA, ANVISA, Turkey, UK MHRA, WHO, etc and has been primarily servicing Ranbaxy for all their submissions globally. After Ranbaxy has been acquired by Sun Pharma, Fortis decided to sell out the company.

Quest Life Sciences has moved the entire facility to Kandla, Gujarat in the Special Economic Zone where Quest is setting up a state-of-the-art BA/BE centre and is likely to be commissioned by June, 2015.

T S Jaishankar, managing director, Quest Life Sciences P Ltd, Chennai informed that their present capacity in Chennai is almost fully utilized and the Kandla venture has been primarily initiated because of the speed and single window clearance of the Gujarat government.

Quest Life Sciences has been audited 5 times by US FDA besides MHRA UK, Spanish Govt, AEMPS, MOH Malaysia, etc.

The construction is nearing completion and hence FCRL acquisition has been at the most opportune time.

Quest has now opened offices in New Jersey, USA, Moscow and Bangkok; besides Kandla and Chennai.